Bristol Myers Squibb Co. has identified nonreceptor tyrosine-protein kinase TYK2 inhibitors reported to be useful for the treatment of amyotrophic lateral sclerosis, Alzheimer's and Parkinson's disease, multiple sclerosis, neuromyelitis optica and optic neuritis.
Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. has described nonreceptor tyrosine-protein kinase TYK2 inhibitors reported to be useful for the treatment of psoriasis, asthma, type 1 diabetes, inflammatory bowel disease, gout, multiple sclerosis, rheumatoid arthritis and TNF receptor-associated periodic syndrome (TRAPS), among others.
Chiesi Farmaceutici SpA has synthesized Janus kinase inhibitors, particularly JAK1, JAK2, JAK3 and nonreceptor tyrosine-protein kinase TYK2 inhibitors, reported to be useful for the treatment of asthma, chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis and acute respiratory distress syndrome.
Allorion Therapeutics Co. Ltd. has patented nonreceptor tyrosine-protein kinase TYK2 inhibitors reported to be useful for the treatment of psoriasis, inflammatory bowel disease, psoriatic arthritis, ulcerative colitis, Crohn's disease and systemic lupus erythematosus.
Medshine Discovery Inc. has patented new sulfinylpyridine-containing nonreceptor tyrosine-protein kinase TYK2 inhibitors expected to be useful for the treatment of Crohn's disease, systemic lupus erythematosus, psoriasis, psoriatic arthritis and ulcerative colitis.
The structure of a potent and selective TYK2 inhibitor, NDI-034858 (NTX-973), which was found clinically effective in autoimmune and inflammatory diseases, was disclosed for the first time by researchers from Nimbus Therapeutics LLC.
